Partial peptide mimetics and methods

Details Partial peptide mimetics and methods Partial peptide mimetics and methods

2006-06-06

2006-06-06

Navarro, Mark (Department: 1645)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Amino acid sequence disclosed in whole or in part; or...

C514S002600, C530S300000, C530S402000

Reexamination Certificate

active

07056514

ABSTRACT:
Partial peptide mimetics and methods of making and using, wherein the partial peptide mimetics have a first amino acid sequence comprising ANIKLSVQMKL (SEQ ID NO:8), a homolog thereof, or a segment of SEQ ID NO:8 or a homolog thereof, a second amino acid sequence comprising IIVKLND (SEQ ID NO:2), a homolog thereof, or a segment of SEQ ID NO:2 or a homolog thereof, and a β-turn inducing scaffold bonded between the first and second amino acid sequences.

REFERENCES:
patent: 5089274 (1992-02-01), Marra et al.
patent: 5171739 (1992-12-01), Scott
patent: 5190873 (1993-03-01), Lernhardt et al.
patent: 5198541 (1993-03-01), Elsbach et al.
patent: 5334584 (1994-08-01), Scott et al.
patent: 5348942 (1994-09-01), Little, II et al.
patent: 5595877 (1997-01-01), Coolidge et al.
patent: 5639725 (1997-06-01), O'Reilly et al.
patent: 5786324 (1998-07-01), Gray et al.
patent: 5830860 (1998-11-01), Gray et al.
patent: 5837678 (1998-11-01), Little, II
patent: 5837682 (1998-11-01), Folkman et al.
patent: 5854205 (1998-12-01), O'Reilly et al.
patent: 5854214 (1998-12-01), Little, II
patent: 5856302 (1999-01-01), Ammons et al.
patent: 5955577 (1999-09-01), Mayo
patent: 6486125 (2002-11-01), Mayo
patent: 2002/0146406 (2002-10-01), Mayo
patent: WO 89/01486 (1989-02-01), None
patent: WO 90/09183 (1990-08-01), None
patent: WO 92/09621 (1992-06-01), None
patent: WO 92/09695 (1992-06-01), None
patent: WO 93/05797 (1993-04-01), None
patent: WO 93/23434 (1993-11-01), None
patent: WO 94/14819 (1994-08-01), None
patent: WO 94/18323 (1994-08-01), None
patent: WO 94/20532 (1994-09-01), None
patent: WO 94/25476 (1994-11-01), None
patent: WO 95/00641 (1995-01-01), None
patent: WO 95/01428 (1995-01-01), None
patent: WO 95/02414 (1995-01-01), None
patent: WO 96/31528 (1996-10-01), None
patent: WO 96/37212 (1996-11-01), None
patent: WO 97/44354 (1999-11-01), None
VERMA, “Improved Genomic Blot Hybridization,” Bio/Tech., 7, 934 (1989).
Altieri et al., “Association of Biomolecular Systems via Pulsed Field Gradient NMR Self-Diffusion Measurements,”J. Am. Chem. Soc., 117, 7566-7567 (1995).
Anisowicz et al., “Constitutive overexpression of a growth-regulated gene in transformed Chinese hamster and human cells,”Proc. Natl. Acad. Sci. USA, 84, 7188-7192 (1987).
Bangalore et al., “Identification of the Primary Antimicrobial Domains in Human Neutrophil Cathespin G,”J. Biol. Chem., 265(23), 13584-13588 (1990).
Battafarano et al., “Peptide derivatives of three distinct lipopolysaccharide binding proteins inhibit lipopolysaccharide-induced tumor necrosis factor-a secretion in vitro”, Surgery 1995; 118:318-324.
Bax et al., “MLEV-17-Based Two-Dimensional Homonuclear Magnetization Transfer Spectroscopy,”J. Magnetic Resonance, 65, 355-360 (1985).
Beamer et al., “Crystal Structure of Human BPI and Two Bound Phospholipids at 2.4 A Resolution”, Science, 276, 1861-1864 (1997).
Bakele et al., “Improved Synthesis of the Boc and Fmoc Derivatives of 4-(2'-Aminoethyl)-6-dibenzofuranpropionic Acid: An Unnatural Amino Acid That Nucleates .beta.-Sheet Folding” J. Org. Chem., 62, 2259-2262 (1997).
Blanco et al., “A short linear peptide that folds into a native stable β-hairpin in aqueous solution,”Structural Biology, 1, 584-590 (1994).
Boehm et al., “Antiangiogenic Therapy of Experimental Cancer does not Induce Acquired Drug Resistance”, Nature, 390, 404-407 (1997).
Bone et al., “A second large controlled clinical study of E5, a monoclonal antibody to endoxtoxin: Results of a prospective, multicenter, randomized, controlled trial,”Critical Care Medicine, 23, 994-1005 (1995).
Bottone et al., “Association ofPseudomonas cepaciawith Chronic Granulomatous Disease,”J. Clin. Microbiol., 1(5), 425-428 (1975).
Brown et al., “[8]Chemical Synthesis and Cloning of a Tyrosine tRNA Gene,”Methods in Enzymology, 68, 109-151 (1979).
Brunger, X-Plor Manual, Yale University Press, New Haven (1992).
Bryson et al., “Protein Design: A Hierarchic Approach,”Science, 270, 935-941 (1995).
Budson et al., Biochem. Biophys. Res. Comm., 225, 141-145 (1996).
Campanelli et al., “Azurocidin and a Homologous Serine Protease from Neutrophils—Differential Anticmicrobial and Proteolytic Properties,”J. Clin. Invest., 85, 904-915 (1990).
Cantor et al., “The behavior of biological macromolecules,”Biophysical Chemistry, Part III, 979-1039 (1980).
Capone, “Screening Recombinant Baculovirus PlaquesIn Situwith Antibody Probes,”Gene Anal. Techn., 6, 62-66 (1989).
Carpino, “I-Hydroxy-7-azabeiizotriazole. An Efficient Peptide Coupling Additive,”J. Am. Chem. Soc., 115, 4397-4398 (1993).
Casey et al., “Neisseria GonorrhoeaeSurvive Intraleukocytic Oxygen—Independent Antimicrobial Capacities of Anaerobic and Aerobic Granulocytes in the Presence of Pyocin Lethal for Extracellular Gonococci”. Infect. Immun.52:384-389 (1986).
Chen et al., “Characterization of the WW domain of the human Yes-associated protein and its polyproline-containing ligands” J. Biol. Chem. 272:17070, 1997.
Cody et al., Int. Surg. Res., 52:315, 1992).
Dahlberg et al., “A Novel Endotoxin Antagonist Attenuates Tumor Necrosis Factor-α Secretion,”Journal of Surgical Research, 63, 44-48 (1996).
D'Amato et al., “Thalidomide is an Inhibitor of Angiogenesis,”Proc. Natl. Acad. Sci. USA, 91(9):4082-4085 (1994).
Dameron et al., “Control of Angiogenesis in Fibroblasts by p53 Regulation of Thrombospondini-1,”Science, 265:1582-1584 (1994).
Daopin et al., “Crystal Structure of Transforming Growth Factor-Beta 2: An Unusual Fold for the Superfamily”, Science, 257, 369-373 (1992).
Delaglio et al., “NMRPipe: a multidimensional spectral processing system basedon UNIX pipes”, J. Biomol. NMR, 6, 277-293 (1995).
Deuel et al., “Amino acid sequence of human platelet factor 4,”Proc. Natl. Acad. Sci. USA, 74, 2256-2258 (1977).
Diaz et al., “Design, Synthesis, and Partial Characterization of Water-Soluble β-sheets stabilized by a Dibenzofuran-Based Amino Acid”, J. Am. Chem. Soc., 115, 3790-3791 (1993).
Dikler et al., “Improving Mass Spectrometric Sequencing of Arginin Containing Peptides by Derivatization with Acetylacetone” J. Mass. Spectrom. 32:1337, 199.
Dings et al., “The designed antiostatic peptide anginex synergistically improves chemotherapy and antiangiogenesis therapy with angiostatin” Cancer Res., 63, 382-385 (2003).
Dintzis et al., “A Comparison of the Immunogenicity of a Pair of Enantiomeric Proteins,”Proteins: Structure, Function, and Genetics, 16(3), 306-308 (1993).
Dugas et al.,Bioorganic Chemistry, Springer-Verlag, New York, NY (1981), Title Page, Copyright Page, Table of Contents, and pp. 54-92.
Dunn et al., “Efficacy of type specific and cross reactive murine monoclonal antibodies directed against endotoxin during experimental sepsis”, Surgery, 98:283, 1985.
Eck et al., “The Structure of Human Lymphotoxin (Tumor Necrosis Factor-Beta) at 1.9 A Resolution”, J. Biol. Chem., 267, 2119-2122 (1992).
Elsbach et al., “Bactericidal/permeability increasing protein and host defense against Gram-negative bacterial and endotoxin,”Curr. Opn. in Imm., 5(1), 103-107 (1993).
Farley et al., “Lipopolysaccharide Structure Determinies Ionic and Hydrophobic Binding of a Cationic Antimicrobial Neutrophil Granule Protein,”Infect. Immun., 56, 11589-1592 (1988).
Fields et al., in Synthetic Peptides: A User's Guide, W.M. Freeman & Company, New York, NY, pp. 77-183 (1992).
Folkman et al., “Angiogenesis in Cancer, Vascular, Rheumatoid and other Disease”, Nature Med., 1, 27-31 (1995).
Folkman, “What is the evidence that tumors are angiogenesis dependent”, J. Natl. Cancer. Inst., 82, 4-6 (1990).
Folkman et al., “Angiogen

Affiliated with

Also associated with

Rating

Partial peptide mimetics and methods does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Partial peptide mimetics and methods, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Partial peptide mimetics and methods will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3649704